Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514680 · ClinicalTrials.gov registry record · NA
Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 226
- Enrollment target
NCT03514680: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT03514680 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 226 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03514680, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
Study Summary
This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.
Primary Outcome
Frequency of clinician CIPN assessment and management documentation for each period.
Interventions
- BEHAVIORAL CIPN Assessment and Management Algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-03-23 |
| Phase | NA |
What the finished NCT03514680 record still lists
NCT03514680 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which CIPN Assessment and Management Algorithm is the first listed.
NCT03514680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03514680 about?
NCT03514680 is a clinical study titled "Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy". This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.
What is the current status of trial NCT03514680?
This trial is currently completed. It is a NA study. The enrollment target is 226 participants. The study started on 2018-06-04. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT03514680?
The interventions under investigation include: CIPN Assessment and Management Algorithm (BEHAVIORAL).
Who is sponsoring clinical trial NCT03514680?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03514680's enrollment target sits among peer trials
226 471st of 2000 higher than 1,529 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI